
|Articles|September 1, 2001
- Pharmaceutical Executive-09-01-2001
- Volume 0
- Issue 0
Profits and Promotion Under Attack
As policy makers struggle to devise a pharmacy benefit for Medicare patients, pressure mounts to impose spending limits on medications. In turn, consumer activists are challenging industry’s longtime claim that price controls will reduce investment in R&D for life-saving therapies.
Advertisement
Articles in this issue
almost 25 years ago
New Playing Fieldsalmost 25 years ago
Inefficiencies: Cutting Through the Junglealmost 25 years ago
Legislation: EC Proposes Changesalmost 25 years ago
Flexing Their Budgets: Big Pharma Spend Trendsalmost 25 years ago
Media Mix Town Meeting 2001: Much Ado About MediaAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
3
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
4
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
5




